MOTS-c

Preclinical

Weight Management

A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic function and insulin sensitivity.

Administration

Subcutaneous injection

Dosage Range

5-10 mg weekly

Mechanism of Action

MOTS-c is encoded in mitochondrial DNA and activates AMPK signaling, improving glucose metabolism, enhancing fatty acid oxidation, and mimicking the metabolic benefits of exercise at the cellular level.

Clinical Benefits

Mimics exercise at cellular level

Improves insulin sensitivity

Enhances fat metabolism

Supports mitochondrial function

Reduces metabolic syndrome markers

Clinical Evidence

Discovered at USC in 2015. Preclinical studies demonstrate significant metabolic improvements. Shown to prevent diet-induced obesity and improve insulin resistance in animal models. Human trials in progress.

Side Effects

Injection site reaction

Mild fatigue

Muscle soreness

Contraindications

Pregnancy

Severe metabolic disorders (consult physician)

Active cancer

Related Peptides in Weight Management

Semaglutide

A GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes significant weight loss with cardiovascular benefits.

Tirzepatide

A dual GIP/GLP-1 receptor agonist that delivers superior weight loss and metabolic improvements compared to single-target therapies.

AOD-9604

A modified fragment of human growth hormone (hGH 176-191) that stimulates fat metabolism without the growth-promoting effects of full GH.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.